Table 1. Current method of choice for required tests associated with specific tumour types.

Tumour type	Test required	Method of choice	Other non-essential tests and methods
Breast carcinoma	ERBB2 (HER2)	FISH (dual-colour)/CISH/SISH	Microarray, NGS
Carcinoma	Disease-specific rearrangement	FISH (if available probes) or RT-PCR	Banding, microarray, NGS
Lipomatous tumours	Subtype-specific changes	FISH, banding	Banding, MLPA (dosage)
Neuroblastoma	MYCN status	FISH (dual-colour)	1p, 11q, 17q status (FISH or MLPA), banding, microarray, NGS
Gliomas	1p,19q status	FISH, or qPCR, or MLPA	Microarray, NGS, banding
Other CNS tumours	MGMT methylation; disease- or grade-specific changes	FISH (eg, MYC in medulloblastoma)	Banding, MGMT methylation analysis (MS-MLPA, MS-PCR, pyrosequencing), microarray
Renal tumours	Subtype-specific changes	Banding	Microarray, FISH
Soft tissue sarcoma	Sarcoma-specific fusion product	FISH (if available probes), or RT-PCR, banding	Banding
Wilms tumour			Banding, FISH, microarray